Intervacc publishes the 2025 Annual Report

Intervacc AB (publ) announces that the company's 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on the company's website intervacc.com.

For more information please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 (0)8 120 10 600
E-mail: carl-johan.dalsgaard @intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on April 14, 2026 at 08.30 CET.

About Intervacc
Intervacc AB is an animal health group that develops vaccines for animals. The company’s vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, see intervacc.se

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Date Created
2026-04-14